» Articles » PMID: 22429514

Is It Possible to Estimate the Minimal Clinically Important Treatment Effect Needed to Change Practice in Preterm Birth Prevention? Results of an Obstetrician Survey Used to Support the Design of a Trial

Overview
Publisher Biomed Central
Date 2012 Mar 21
PMID 22429514
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sample sizes for obstetrical trials are often based on the opinion of investigators about clinically important effect size. We surveyed Canadian obstetricians to investigate clinically important effect sizes required before introducing new treatments into practice to prevent preterm birth.

Methods: Questionnaires were mailed to practicing obstetricians, asking the magnitude of pregnancy prolongation required to introduce treatments into practice. The three prophylactic treatments were of increasing invasiveness: vaginal progesterone, intramuscular progesterone, and cervical cerclage. We also asked about the perceived most relevant outcome measures for obstetrical trials and current obstetrical practice in preterm birth prevention.

Results: 544/1293(42.1%) completed questionnaires were received. The majority of respondents required one or two weeks' increase in length of gestation before introducing vaginal (372,77.1%), and intramuscular progesterone(354,67.9%). At least three weeks increase was required before introducing prophylactic cervical cerclage(326,62.8%). Clinicians who already used a treatment required a smaller difference before introducing it into practice. Decreasing neonatal morbidity was cited as the most important outcome for obstetrical trials (349,72.2%).

Conclusion: Obstetricians would require a larger increase in treatment effect before introducing more invasive treatments into practice. Although infant morbidity was perceived as a more important outcome, clinicians appeared willing to change practice on the basis of prolongation of pregnancy, a surrogate outcome. We found that there is not a single minimum clinically important treatment effect that will influence all practising clinicians: rather the effect size that will influence physicians is affected by the nature of the treatment, the reported outcome measure and the clinician's own current clinical practice.

Citing Articles

Effects of Mediterranean Diet or Mindfulness-Based Stress Reduction on Prevention of Small-for-Gestational Age Birth Weights in Newborns Born to At-Risk Pregnant Individuals: The IMPACT BCN Randomized Clinical Trial.

Crovetto F, Crispi F, Casas R, Martin-Asuero A, Borras R, Vieta E JAMA. 2021; 326(21):2150-2160.

PMID: 34874420 PMC: 8652606. DOI: 10.1001/jama.2021.20178.


Associations of prenatal urinary phthalate exposure with preterm birth: the Maternal-Infant Research on Environmental Chemicals (MIREC) Study.

Hu J, Arbuckle T, Janssen P, Lanphear B, Braun J, Platt R Can J Public Health. 2020; 111(3):333-341.

PMID: 32441020 PMC: 7351891. DOI: 10.17269/s41997-020-00322-5.


Using tocolysis in pregnant women with symptomatic placenta praevia does not significantly improve prenatal, perinatal, neonatal and maternal outcomes: a systematic review and meta-analysis.

Morfaw F, Fundoh M, Bartoszko J, Mbuagbaw L, Thabane L Syst Rev. 2018; 7(1):249.

PMID: 30591076 PMC: 6307312. DOI: 10.1186/s13643-018-0923-2.


Progesterone in women with arrested premature labor, a report of a randomised clinical trial and updated meta-analysis.

Wood S, Rabi Y, Tang S, Brant R, Ross S BMC Pregnancy Childbirth. 2017; 17(1):258.

PMID: 28768474 PMC: 5541428. DOI: 10.1186/s12884-017-1400-y.


Pregnant women's preferences for and concerns about preterm birth prevention: a cross-sectional survey.

Ha V, McDonald S BMC Pregnancy Childbirth. 2017; 17(1):49.

PMID: 28143534 PMC: 5286823. DOI: 10.1186/s12884-017-1221-z.


References
1.
Beaton D, Boers M, Wells G . Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002; 14(2):109-14. DOI: 10.1097/00002281-200203000-00006. View

2.
Rode L, Klein K, Nicolaides K, Krampl-Bettelheim E, Tabor A . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011; 38(3):272-80. DOI: 10.1002/uog.9093. View

3.
van Os M, van der Ven J, Kleinrouweler C, Pajkrt E, de Miranda E, van Wassenaer A . Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study. BMC Pregnancy Childbirth. 2011; 11():77. PMC: 3214137. DOI: 10.1186/1471-2393-11-77. View

4.
Brasher P, Brant R . Sample size calculations in randomized trials: common pitfalls. Can J Anaesth. 2007; 54(2):103-6. DOI: 10.1007/BF03022005. View

5.
Crosby R, Kolotkin R, Williams G . Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003; 56(5):395-407. DOI: 10.1016/s0895-4356(03)00044-1. View